Beat AML: Precision Medicine Superior to SOC Beat AML: Precision Medicine Superior to SOC
Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Young survivors of acute myeloid leukemia have long-term complications from treatment
(University of California - Davis Health) Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment, a study led by UC Davis Comprehensive Cancer Center researchers has found. The most common complications were cardiovascular, endocrine and respiratory diseases. The complications - known as late effects - were more present among non-white AYA patients and those living in more deprived neighborhoods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2020 Category: Cancer & Oncology Source Type: news

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
             Basel, 19 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta was previously granted provisional approval in this setting under the FDA ’s accelerated approval programme in November 2018. Today’s FDA approval converts Ve...
Source: Roche Media News - October 19, 2020 Category: Pharmaceuticals Source Type: news

Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
             Basel, 19 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta was previously granted provisional approval in this setting under the FDA ’s accelerated approval programme in November 2018. Today’s FDA approval converts Ve...
Source: Roche Investor Update - October 19, 2020 Category: Pharmaceuticals Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia
South San Francisco, CA -- October 16, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2020 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Genomic markers of midostaurin drug sensitivity in leukemia patients
(Impact Journals LLC) Oncotarget Volume 11, Issue 29 reported that acute myeloid leukemia is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 14, 2020 Category: Cancer & Oncology Source Type: news

Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Financing to advance mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, and potential best-in-class therapy for AML patients DUBLIN, Oct. 12, 2020 -- (Healthcare Sales & Marketing Network) -- Priothera Limited, a clinical stage company... Biopharmaceuticals, Oncology, Venture Capital, Personnel Priothera, mocravimod, sphingosine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 12, 2020 Category: Pharmaceuticals Source Type: news

Factors Associated With Suicide in Leukemia Identified
FRIDAY, Oct. 9, 2020 -- Male sex, older age at diagnosis, White race, and having acute myeloid leukemia are risk factors associated with suicide among patients with leukemia, according to a study published online Oct. 6 in Cancer Medicine. Haohui... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 9, 2020 Category: Pharmaceuticals Source Type: news

Measurable Residual Disease Negativity Tied to Survival in AML
THURSDAY, Oct. 8, 2020 -- For patients with acute myeloid leukemia (AML), achieving measurable residual disease (MRD) negativity is associated with improved survival, according to a review and meta-analysis published online Oct. 8 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 8, 2020 Category: Pharmaceuticals Source Type: news

MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves First Maintenance Therapy for AML FDA Approves First Maintenance Therapy for AML
The FDA has approved an oral formulation of azacitidine for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved initial complete remission.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2020 Category: Drugs & Pharmacology Source Type: news